Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201510-03-2023
10-03-2023
Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, March 16, 2023, inter alia, to consider and declare payment of interim dividend, if any, on Equity Shares for the financial year 2022-23. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window shall remain closed from March 10, 2023 to March 18, 2023 (both days inclusive) for above mentioned purpose.09-03-2023
Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for Inter Alia, To Consider And Declare Payment Of Interim Dividend, If Any, On Equity Shares For The Financial Year 2022-23.
Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2023 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, March 16, 2023, inter alia, to consider and declare payment of interim dividend, if any, on Equity Shares for the financial year 2022-23. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window shall remain closed from March 10, 2023 to March 18, 2023 (both days inclusive) for above mentioned purpose.09-03-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st December, 2022 in respect of utilization of proceeds of the IPO of the Company.13-02-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, January 27, 2023 for the Third quarter and Nine Months ended December 31, 2022 is available on the Company's website at: https://www.glenmarklifesciences.com/pdf/Glenmark Life Sciences-Earnings Call Transcript-Jan- 27_2023.pdf The said transcript is also attached.01-02-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of Q3 FY2022-23 Earnings Call28-01-2023
Glenmark Life Sciences profit rises 1% in Dec quarter on API strength
The Mumbai-based drug maker's profit rose to 1.05 billion rupees ($12.86 million) in the three months ended Dec. 31, from 1.04 billion rupees a year ago27-01-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation.27-01-2023
Q3FY23 Quarterly Result Announced for Glenmark Life Sciences Ltd.
Pharmaceuticals firm Glenmark Life Sciences announced Q3FY23 results: Q3FY23: GLS registered a revenue of Rs 5,407 million for Q3FY23 from operations, recording a growth of 6.2% QoQ and 3.5% YoY. Gross margins for the quarter were at 51.0%, up 20 bps YoY, driven by product mix and PLI scheme benefit EBITDA was at Rs 1,520.6 million for Q3FY23. EBITDA margin at 28.1% remains steady on YoY basis, with a slight sequential decline mainly due lower gross margins PAT for the quarter was at Rs 1,049.9 million in Q3FY23, registering a growth of 1.2% YoY. PAT margin for the quarter was at 19.4%. Gross margins for the quarter were at 51.0%, up 20 bps YoY, driven by product mix and PLI scheme benefit. R&D; expenditure was at Rs 167.6 million, 3.1% of sales. Capital expenditure was at Rs 324 million. ROICE (adjusted for Cash and CWIP) was 32.2% for 9MFY23 and the fixed assets turnover ratio at ~3x. Commenting on the company’s performance, Dr Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited, said, “I am pleased to report that the company has continued its upward trajectory to witness steady growth both on sequential as well as YoY basis on the back of a robust performance of our external business. India, Europe and LATAM were the main catalysts for growth whereas the US witnessed a healthy recovery. The GPL business saw a strong recovery in the current quarter while the CDMO business was sluggish, and we expect it to pick up strongly from Q4 onwards.” Rawjee further added, “During 9MFY23, we launched 5 new products, and we continue to cross-sell our wide product basket to existing customers across different geographies. Overall, as the three levers of the business (External business, GPL and CDMO) are on track to perform well, I am confident of delivering steady growth with stable margins in the coming quarters.” Tushar Mistry, CFO, Glenmark Life Sciences Limited, said, “The company continues to grow steadily with revenue from operations growing 3.5% on YoY basis and 6.2% sequentially. EBITDA for the quarter at 28.1% was steady on YoY basis. Our proactive cost control measures have helped us maintain our EBITDA margins for the nine months at 30%. We are also witnessing increased capacity as Dahej block comes online. That said, we are strategically commissioning the Dahej block module-wise to keep expenses under control which will ensure steady margins in the coming quarters. Our prudent working capital management during the quarter has led to healthy cash flow generation from the operations. Reviving demand in the regulated markets and GPL business supported by excess capacity availability will propel growth in coming quarters.” Result PDF27-01-2023